VerifiedRx Podcast Por Vizient Center for Pharmacy Practice Excellence arte de portada

VerifiedRx

VerifiedRx

De: Vizient Center for Pharmacy Practice Excellence
Escúchala gratis

OFERTA POR TIEMPO LIMITADO | Obtén 3 meses por US$0.99 al mes

$14.95/mes despues- se aplican términos.
Delivering short doses of insight for hospitals’ frontline pharmacy professionals, the Vizient pharmacy team brings together experts to verify best practices for navigating today’s pharmacy practice challenges and accelerating career growth. It’s a prescription for success, delivered by the Vizient Center for Pharmacy Practice Excellence.Copyright 2025 All rights reserved. Ciencia Economía Enfermedades Físicas Gestión Gestión y Liderazgo Higiene y Vida Saludable
Episodios
  • The GOAT of GPO’s

    The GOAT of GPO’s
    Dec 30 2025
    Pharmacy buyers play a critical role in keeping hospitals running—and their partnership with a GPO can make all the difference. In this episode of Verified Rx, Jackie Stokes sits down with Theresa Brown and Michelle Crump, two powerhouse pharmacy buyers and members of Vizient’s Pharmacy Technician Committee, to talk about the tools, programs, and peer networks that help them thrive in their roles. From leveraging pharmacy analytics to navigating shortages, maximizing NovaPlus value, and strengthening buyer-to-buyer collaboration, this episode is packed with insights to help pharmacy teams work smarter, save money, and support better patient care. Guest speakers: Theresa Brown National Pharmacy Purchasing Specialist Prospect Medical Holdings Michelle Crump, ASBA, CPhT National Certified Pharmacy Technician Buyer Pharmacy Host: Jackie Stokes Program Services Manager Center for Pharmacy Practice Excellence (CPPE) Vizient Show Notes: [00:48] — Guest Introductions Theresa National pharmacy purchasing specialistBackground: inventory control, home infusion startup, pharmacy technician educator [01:14] — Michelle Nationally certified pharmacy technician since 2016Pharmacy buyer at a small independent county critical access hospitalTransitioned from accounting into pharmacy purchasing [01:26] — The Role of Vizient in Supporting Pharmacy Buyers Theresa: Biggest benefit: relationship with pharmacy executive & sourcing teamUses Pharmacy Analytics (formerly VSAP) to evaluate spend and inventory control across 63 facilities [02:16] — How Pharmacy Analytics Supports Buyers Theresa: Data mining on spend increases/decreasesTracks product returnsIdentifies sharing opportunities to prevent waste [02:59] — Michelle’s Experience Analytics helps mitigate wasteCollaboration with other buyers has been essential — especially for someone new to the buyer roleLearns navigation of Vizient systems and how to work with the local GPOPeer support helps demystify a “diverse and complex” buyer role [04:02] — Value of the Vizient Pharmacy Technician Committee Provides national peer networkingHelps buyers learn from subject matter expertsEven highly experienced buyers (35+ years) learn from every call [04:41] — Vizient Programs: NovaPlus, NES, Forum Calls, Hot Info Bimonthly Forum Calls Provide regulatory updatesHelp expand buyer knowledge in real time Hot Info Weekly Updates Keeps users informed on inventory, shortages, spend impacts [05:31] — Michelle on Program Impact Calls and shared expertise were critical when she was newNovaPlus program especially valuable in critical access settings [06:32] — Deep Dive: How the NovaPlus Program Works Michelle explains: NovaPlus (Y-label) aligns with manufacturer-labeled products (M-label)Quarterly rebates provide significant savingsCritical access hospitals benefit via 340B optimizer software that extracts outpatient utilization to qualify for discounted M-label purchasingCan result in “significant savings” depending on contract structure [08:38] — What If NovaPlus Pricing Isn’t the Best Price? Michelle: Buyer’s responsibility to identify price discrepanciesCommunicates with Vizient representative to reassess contracting needsOften resolved through rebates or future price adjustments [09:30] — Theresa: Price challenges taken seriouslyMany result in price reductions visible in Hot Info the next weekDemonstrates importance of strong GPO relationships [10:07] — Understanding NES: NovaPlus Enhanced Supply Theresa: Her hospitals are exploring NES participationRequires 90% compliance (higher than standard 80%)Benefits include prioritized product access during shortagesCritical when national backorders exceed 200+ itemsEnsures better patient care continuity [11:34] — Supply Assurance & Mitigation Strategies Michelle: During the North Carolina hurricane, Vizient’s mitigation strategy was “imperative”Vizient engaged Baxter directly to resolve critical fluid shortagesSmall hospitals especially reliant on support in crisis situations [12:36] — Theresa: Shortage team provides substitution guidance and clinical appropriateness informationVizient recommendations support discussions with local clinical teamsCrucial during COVID start date — her first day in national role [13:23] — Continuing Education (CE) Programs Theresa: Vizient CE programs help maintain technician licensureWebinars are interactive, engaging, and more informative than generic CE resources [14:07] — Networking and Pharmacy Aggregation Groups (PAGs) Theresa: PAGs offer cost savings and peer collaborationAbility to share information and bring value back to her own network [14:44] — Michelle’s Example of System-to-System Collaboration Shared compounded syringes (from a 503B facility) with another hospital to prevent wasteHighlights real-world benefits of PAG networking [15:52] — Addressing National Challenges Together Theresa: PAG ...
    Más Menos
    19 m
  • Return of Pipeline 2026 – Cell and Gene Therapies

    Return of Pipeline 2026 – Cell and Gene Therapies
    Dec 9 2025
    In Part 2 of the 2026 pipeline series, host Carolyn Liptak welcomes Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient, to explore the advanced therapies pipeline: cell therapies, gene therapies, tissue-engineered products, and combination advanced therapy products. The discussion explores major pipeline trends, six leading products to watch, and the growing innovation expected to shape clinical practice in 2026. Guest speakers: Amanda Frick, PharmD, BCPS Senior Clinical Manager, Strategic Clinical Intelligence Spend Management Vizient Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director Center for Pharmacy Practice Excellence (CPPE) Vizient Show Notes: [00:05] — Introduction Announcer opens the episode.Host Carolyn Liptak introduces the focus on advanced therapies: cell & gene therapies, tissue-engineered products, and combination products.Guest: Dr. Amanda Frick, Senior Clinical Manager, Strategic Clinical Intelligence at Vizient. [01:07] — Defining Advanced Therapies FDA groups cell and gene therapies within advanced therapies.Total FDA-approved advanced therapies: 46.Amanda monitors 29 drug-like therapies within that group. [02:01] — Pipeline Size and Approval Activity S. pipeline: 264 agents in development.About 10 agents approach FDA decision annually.Actual approvals: 5–7 per year on average. [02:56] — Big-Picture Trends in Cell & Gene Therapy Oncology dominates 40–50% of all CGTs in development.Expanding into autoimmune, neurology, and earlier-phase therapies for diabetes, angina, osteoarthritis. Movement toward allogeneic ("off-the-shelf") therapies Designed to overcome limits of autologous cell manufacturing.Reduces wait time and manufacturing failures. Resurgence of therapeutic vaccines Currently 3 approved (Sipuleucel-T, Talimogene, Papzimeos).20+ vaccines in the pipeline, largely targeted to cancer.CE program coming Jan 29. [06:13] — Therapy #1: Tabelecleucel or Tab-cel (Allogeneic EBV-Specific T-Cell Therapy) First allogeneic T-cell therapy expected in the U.S.For EBV-positive post-transplant lymphoproliferative disorder (PTLD).“Off-the-shelf” and donor-derived. [07:07] — Clinical Need & Outcomes Currentstandard of care: rituximab.After relapse, survival <1 month (HSCT) or <4 months (solid organ).Phase 3 data: 90% one-year survival. Regulatory Status Prior FDA CRL due to manufacturing (third-party issues).Expected approval: January 10, 2026. [09:00] — Therapy #2: Kresladi (Autologous Gene Therapy for LAD-I) Treats severe leukocyte adhesion deficiency (LAD-I), typically diagnosed in infancy.Could eliminate need for stem cell transplant (often limited by lack of matched donors). [11:39] — Clinical Outcomes Phase 1/2 data (n=9): 100% survival at one yearMajor reduction in hospitalizationsDiscontinuation of prophylactic antibiotics Regulatory Status Multiple delays due to CMC (chemistry, manufacturing, controls) questions.Resubmitted Oct 2025; anticipated approval March 28, 2026. [13:27] — Therapy #3: ORCA-T (Enhanced Allogeneic Stem Cell Transplant) Allogeneic hematopoietic stem cells + regulatory and conventional T cells (Tregs + Tcons).Designed to improve: Graft-versus-tumor effectGraft-versus-infection protectionReduction in graft-versus-host disease (GVHD) [14:31] — Clinical Significance Could markedly improve quality of life after transplant. Regulatory Status Anticipated approval: April 6, 2026. [15:01] — Therapy #4: Vusolimogene oderparepvec (RP1) (RP1 — Oncolytic HSV-1 Virus) Off-the-shelf genetically modified HSV-1 oncolytic virus.For advanced melanoma after prior PD-1 inhibitor therapy. [16:17] — Why It Matters Currently, poised to compete with Amtagvi (TIL therapy).TIL therapy is autologous and slow to manufacture; RP1 is ready-to-use and combines with nivolumab (Opdivo). Regulatory Status PDUFA: April 10, 2026. [16:34] — Therapy #5: INO-3107 (Therapeutic Vaccine for RRP) Targets HPV 6 and 11, which cause recurrent respiratory papillomatosis (RRP).Patients can require several surgeries per year to remove papillomas. [17:34] — Vaccine Mechanism DNA plasmid (vs viral vector in PAP).Lower insertional oncogenesis risk.Potentially improved durability of response. Regulatory Status Manufacturer aims to finish BLA by end of 2025.Expected approval (with priority review): mid–late 2026. [19:17] — Therapy #6: Clemidsogene lanparvovec (Intracerebral Gene Therapy for Hunter Syndrome) One-time treatment for MPS II (Hunter syndrome).Designed to deliver therapy directly into the brain to address neurological progression. [21:21] — Competing Agent Emerging New enzyme therapy tivedenofusp alfa crosses the blood-brain barrier — unlike current ERT (idursulfase).Expected approval: April 5, 2026.Raises payer & clinical sequencing questions: One-time gene therapy vs repeat annual enzyme therapyDurability vs cost (ERT ~$500K/year) Regulatory Status Clemidsogene lanparvovec anticipated ...
    Más Menos
    24 m
  • Pipeline 2026: The Movers, the Shapers, & What Matters

    Pipeline 2026: The Movers, the Shapers, & What Matters
    Nov 25 2025
    If you're wondering which therapies may influence care delivery, budgets, and decision making in 2026, the pipeline offers an early preview and it points to a year defined by innovation. We're seeing new first in class treatments, thoughtful next generation agents, and a biosimilar market where fewer launches are offset by important competitive shifts driven by recent approvals. John Schoen and Heather Pace from the Center for Pharmacy Practice Excellence join Stacy Lauderdale, Associate Vice President of Evidence-Based Medicine and Drug Information and your Verified RX program host to highlight pipeline agents worth watching and discuss what they may mean for care delivery and spend management in the year ahead. Guest speakers: John Schoen, PharmD, BCPS  Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence  Heather Pace, PharmD Senior Clinical Manager of Drug Information   Vizient Center for Pharmacy Practice Excellence  Host:  Stacy Lauderdale, PharmD, BCPS  Associate Vice President Vizient Center for Pharmacy Practice Excellence Show Notes: [01:01] — Episode Scope The focus is non-CGT therapies; CGT pipeline will be covered in Part 2. [01:50] — Therapeutic Areas With the Most Approvals Oncology leads the pipeline.Others include infectious disease, neurology, rare disease, endocrine, hepatology, dermatology, and rheumatology. [02:37] — Biosimilars in 2026: Momentum or Headwinds? Discussion of potential “biosimilar void”—only 10% of expiring biologic patents have biosimilars in development.Emerging role of PBM private-label biosimilars. [03:51] — FDA Draft Guidance on Interchangeability FDA exploring interchangeable designation for all biosimilars.Potential shift away from clinical efficacy studies in favor of analytical comparisons.Guidance still in draft and open for public comment. [05:34] — John’s Top Picks for First-in-Class Agents 06:11 — Orviglance First manganese-based, oral MRI contrast agent.Advantages for patients with kidney impairment.Used for liver imaging. [06:20] — Why Non-Gadolinium Matters Lower risk of nephrogenic systemic fibrosis. [06:46] — Tabelecleucel First allogeneic EBV-specific T-cell therapy.For EBV-positive PTLD post-transplant.Could become new standard of care. [07:42] — Tanruprubart First therapy specifically for severe Guillain-Barré Syndrome (GBS). Shows improved outcomes over IVIG and plasma exchange. [08:20] — Comparing to Standard of Care Review of improved real-world data outcomes. [09:03] — Therapies That May Shift Care Delivery [09:32] — Icotrokinra: First oral IL-23 antagonist for plaque psoriasis. [10:00] — Insulin Icodec First once-weekly basal insulin for type 2 diabetes.Resubmitted after safety concerns in type 1 diabetes. [10:59] — Honorable Mentions Camizestrant SERD for ER+/HER2– metastatic breast cancer. Ensitrelvir (COVID-19) Oral option for pre-exposure prophylaxis.Also being evaluated for treatment. Doravirine + Islatravir (HIV) Introduces new NRTTI class. Cefepime + Zidebactam Active against metallo-β-lactamase–producing organisms. 14:05 — Key Biosimilar Launches Omalizumab (Xolair) First biosimilars in asthma/allergy space. Aflibercept (Eylea) High competition expected pending litigation. Pertuzumab (Perjeta) First biosimilar anticipated in oncology. [15:31] — Biosimilars Approved in 2025, Impacting 2026 Ustekinumab (Stelara): first full year of competitionDenosumab (Prolia/Xgeva): 10–15 biosimilars expectedEculizumab (Soliris): notable for rare disease market entry [17:17] — John’s Closing Thoughts Strong mix of first-in-class advances and next-gen convenience therapies. [17:36] — Heather’s Closing Thoughts 2026 will focus on speed and scale after the 2025 biosimilar wave.Pharmacists pivotal in ensuring smooth patient transitions. VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
    Más Menos
    19 m
Todavía no hay opiniones